Virios Therapeutics to Present at the SNN Network Summer Virtual Conference
August 11 2021 - 7:05AM
Business Wire
Virios Therapeutics, Inc. (Nasdaq: VIRI), a
clinical-stage biotechnology company focused on advancing novel
antiviral therapies to treat debilitating chronic diseases,
announced today that Greg Duncan, Chairman and Chief Executive
Officer, will present a company overview at the SNN Network Summer
Virtual Conference on August 19, 2021 at 9:00 a.m. ET.
The presentation will focus on the role of activated viruses
triggering a wide range of conditions, including fibromyalgia
(“FM”), irritable bowel syndrome and fatigue-related disorders, and
progress in its currently enrolling Phase 2b FM clinical trial.
Management will be available for one-on-one meetings to be held
throughout the conference.
The live and archived replay of the presentation may be accessed
on the Virios Therapeutics website under the Investors section:
Events and Presentations.
About Virios Therapeutics
Virios Therapeutics (Nasdaq: VIRI) is a clinical-stage
biotechnology company focused on advancing novel antiviral
therapies to treat debilitating chronic diseases, such as
fibromyalgia (“FM”). Immune responses related to the activation of
tissue resident Herpes Simplex Virus-1 (“HSV-1”) have been
postulated as a potential root cause triggering and/or sustaining
chronic illnesses such as FM, irritable bowel disease (“IBS”),
chronic fatigue syndrome and other functional somatic syndromes,
all of which are characterized by waxing and waning symptoms with
no obvious etiology. Our lead development candidate (“IMC-1”) is a
novel, proprietary, fixed dose combination of famciclovir and
celecoxib designed to synergistically suppress HSV-1 replication,
with the end goal of reducing virally promoted disease
symptoms.
Evidence of IMC-1’s efficacy on a broad spectrum of FM outcome
measures was previously demonstrated in a Phase 2a clinical trial.
These trial results are suggestive that IMC-1 may represent a new
and novel treatment for fibromyalgia. IMC-1 has been granted fast
track designation by the FDA and is currently being tested in a
multi-center, randomized, double-blind, placebo-controlled Phase 2b
trial (“FORTRESS”) designed to set the stage for registrational
studies. The company is led by an executive team highly experienced
in the successful development and commercialization of novel
therapies. For more information, please visit www.virios.com.
Forward-Looking Statements
Statements in this press release contain “forward-looking
statements” that are subject to substantial risks and
uncertainties. All statements, other than statements of historical
fact, contained in this press release are forward-looking
statements. Forward-looking statements contained in this press
release may be identified by the use of words such as “anticipate,”
“believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,”
“seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,”
“target,” “aim,” “should,” "will” “would,” or the negative of these
words or other similar expressions, although not all
forward-looking statements contain these words. Forward-looking
statements are based on Virios Therapeutics’ current expectations
and are subject to inherent uncertainties, risks and assumptions
that are difficult to predict, including risks related to the
completion and timing of the Phase 2b trial. Further, certain
forward-looking statements are based on assumptions as to future
events that may not prove to be accurate. These and other risks and
uncertainties are described more fully in the section titled “Risk
Factors” in the Annual Report on Form 10-K for the year ended
December 31, 2020 filed with the Securities and Exchange
Commission. Forward-looking statements contained in this
announcement are made as of this date, and Virios Therapeutics,
Inc. (VIRI) undertakes no duty to update such information except as
required under applicable law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210811005050/en/
Dave Gentry 1-800-733-2447 +1-407-491-4498 dave@redchip.com
or
ir@virios.com
Virios Therapeutics (NASDAQ:VIRI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Virios Therapeutics (NASDAQ:VIRI)
Historical Stock Chart
From Apr 2023 to Apr 2024